Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HH018-sesutecan
- Development stage
- Preclinical
- Lead developer
- Huahui Health
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
HH018-sesutecan is a preclinical antibody-drug conjugate (ADC) developed by Huahui Health. It targets the tumor microenvironment by binding to CD98 (also known as SLC3A2), a protein highly expressed in various cancers. The ADC uses sesutecan, a proprietary exatecan-based linker-payload, to deliver cytotoxic activity selectively to cancer cells expressing CD98. Preclinical studies have demonstrated robust anti-tumor efficacy across multiple cancer types with favorable pharmacokinetics and safety profiles. The drug is being developed for oncology indications, particularly solid tumors that express CD98[1][2][3].
- Brand names
- HH018-sesutecanHH-018-sesutecanHH 018-sesutecan
- Other names
- none
02
Targets
SLC3A2 (Solute carrier family 3 member 2)
Beyond the preview
Go deeper on HH018-sesutecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HH018-sesutecan.